LifeVantage spent most of the last decade building its reputation on a single idea: that a supplement called Protandim could slow the cellular wear-and-tear that comes with aging. The pitch worked well enough to push annual revenue past $220 million by 2021. Then the company chased the weight-loss boom with a product called the MindBody GLP-1 System, revenue jumped double digits in fiscal 2025, and the stock briefly looked like it had found a second act. The November 9 quarterly filing ended that story, at least for now.
What matters here
The math shows a business that swung from profit to loss in a single quarter, driven almost entirely by one product line losing momentum. The mood, measured by today’s price, sits well below the company’s own decade-average valuation. The open question is whether the LoveBiome acquisition and a restructured calendar year give management enough new material to reverse a customer count that is still falling.
Two numbers that should not coexist
LifeVantage’s board approved a $60 million share repurchase program, of which $58.5 million remains unspent as of September 30, 2026. In the same quarter, the company posted a net loss. A company confident enough in its own future to authorize nearly its entire annual revenue in buybacks did not spend a dollar of it, and simultaneously slipped into the red. Those two facts sit in the same filing, and the tension between them is the story.
The 10-Q filed November 9, 2026, covering the quarter ended September 30, 2026, shows revenue of $37.1 million, down roughly a fifth from the same quarter a year earlier. To feel that drop at kitchen-table scale: imagine a small business that collected about $48,000 last autumn collecting only $37,000 this autumn, with fixed costs largely unchanged. The net result was a loss where a solid profit had existed twelve months before, a sign that the cost base did not shrink as fast as the revenue did.
What broke, and what was bought to fix it
Management’s own language in the November 9 earnings release points to two culprits: fewer active customer accounts and sharply lower sales of the MindBody GLP-1 System. The GLP-1 product was the engine of last year’s revenue surge, per our data computed from the fiscal 2026 10-K. When that engine stalled, there was nothing else large enough to hold the line.
The partial offset came from LoveBiome, a gut-health product line LifeVantage acquired in October 2025. The dossier confirms it contributed some sales this quarter, but the filing does not break out a specific figure, so we cannot say how much. What the geography does tell us: Americas revenue fell sharply to $29 million, and Asia-Pacific and Europe fell by a similar proportion to $8.2 million. The decline was not a regional story. It was company-wide.
For a saver trying to read the business, the customer-count decline is the more durable concern. Revenue from a product launch can bounce; a shrinking base of active accounts is a structural problem that takes time and marketing spend to reverse.
The calendar-year pivot
Buried in the same filing is a procedural change that matters more than it sounds. On September 29, 2026, LifeVantage’s board approved switching the company’s fiscal year end from June 30 to December 31. The stated reason is to align reporting with the calendar year, which is standard practice and makes comparisons with peers easier. The practical effect is a transition period that will produce a short, stub fiscal year, making the next several quarters harder to compare cleanly against history. Investors reading the next few filings will need to track which period is which.
Reading the numbers
- $37.1 million quarterly revenue (Q1 FY2027, ended September 30, 2026). What it is: total sales for the quarter. What it means here: the company is running at an annualized pace well below the $183 million our data shows for full fiscal 2026, suggesting the revenue decline accelerated into the new fiscal year. Everyday example: a shop that did $183,000 last year is now on pace closer to $148,000, if this quarter’s rate holds.
- 22% revenue decline year-over-year. What it is: the percentage drop from $47.6 million to $37.1 million. What it means here: roughly one dollar in five of last year’s sales did not come back. Everyday example: a household that earned $4,760 in freelance work last autumn earned about $3,710 this autumn doing the same work.
- Net loss of $0.2 million versus net income of $2.2 million a year ago. What it is: the bottom line, after all costs. What it means here: the business crossed from profitable to unprofitable in twelve months, a swing of about $2.4 million on roughly $10 million less revenue. That math says costs did not fall nearly as fast as sales.
- $58.5 million remaining under the $60 million buyback program. What it is: authorized but unspent capacity to repurchase shares. What it means here: the board approved the program but did not deploy it this quarter, which may reflect caution about cash while revenue is falling. A buyback spends real cash; not using it preserves flexibility.
- P/E of 12.0 versus a decade median of 15.6 (our data). What it is: the price-to-earnings multiple, meaning the price tag the market puts on each dollar of annual profit. What it means here: the stock is priced at a discount to its own history. Everyday example: a business that historically sold for $15.60 per dollar of annual profit is selling today for $12.00 per dollar, about 23% cheaper than its own norm.
Sources
- 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended June 30, 2026 (SEC EDGAR)
- 10-Q for quarter ended September 30, 2025 (SEC EDGAR)
- LifeVantage Q1 FY2027 earnings release (GlobeNewswire, November 9, 2026)
- LifeVantage Q1 FY2027 results summary (StockTitan)









